Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › GLORY-1

GLORY-1

Mazdutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Mazdutide
Population
obesity
Official title
A Study of IBI362 in Participants With Obesity or Overweight
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
3
Registry status
completed · 2022-11 → 2023-08
Participants
610
Duration
48 weeks
Registry
NCT05607680

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
mazdutide 4 mgobesity china48——−11.0 % vs +0.3 %
Δ −11.3 pp
—1.5 vs 1.011.3 vs 5.432.5 vs 5.926.1 vs 2.95.9 vs 6.3—verified
mazdutide 6 mgobesity china48——−14.0 % vs +0.3 %
Δ −14.3 pp
—0.5 vs 1.010.9 vs 5.450.5 vs 5.943.1 vs 2.94.0 vs 6.3—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (12)
  • mazdutide 4 mg · weight_tp · Table 2 (week 48, key secondary end point)
    | Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
  • mazdutide 4 mg · ae_dc · Table 4
    | Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5)
  • mazdutide 4 mg · disc_any · Results, Participants, paragraph 1
    trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
  • mazdutide 4 mg · nausea · Table 4
    | Nausea | 66 (32.5)
  • mazdutide 4 mg · vomiting · Table 4
    | Vomiting | 53 (26.1)
  • mazdutide 4 mg · sae · Table 4
    | Serious adverse event | 12 (5.9)
  • mazdutide 6 mg · weight_tp · Table 2 (week 48, key secondary end point)
    | Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
  • mazdutide 6 mg · ae_dc · Table 4
    | Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5) | 1 (0.5)
  • mazdutide 6 mg · disc_any · Results, Participants, paragraph 1
    trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
  • mazdutide 6 mg · nausea · Table 4
    | Nausea | 66 (32.5) | 102 (50.5)
  • mazdutide 6 mg · vomiting · Table 4
    | Vomiting | 53 (26.1) | 87 (43.1)
  • mazdutide 6 mg · sae · Table 4
    | Serious adverse event | 12 (5.9) | 8 (4.0)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: GLORY-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.